[Featured Stock] JinMatrix Hits Upper Limit on News of Delta Defense for COVID-19 Vaccine Candidate

[Image source=Yonhap News]

[Asia Economy Reporter Ji Yeon-jin] On the 2nd, JinMatrix's stock price soared to the upper limit after news that its COVID-19 vaccine candidate showed 100% protective efficacy against the Delta variant.

JinMatrix is trading at 12,950 KRW, up 29.63% from the previous day, just five minutes after the opening of the KOSDAQ market on the same day.

Earlier, the company announced that in a virus challenge test conducted by the International Vaccine Institute (IVI), an internationally accredited vaccine research organization, its COVID-19 vaccine candidate (GM-ChimAd-CV) group demonstrated 100% protective efficacy against the Delta variant.

According to the company, the challenge test, which evaluates the survival rate of test animals infected with the actual virus along with neutralizing antibody titers, is considered the most definitive primary indicator to determine the efficacy of the test vaccine.

JinMatrix's vaccine candidate was developed based on its proprietary next-generation 'GM-ChimAd' viral vector technology. This vector is characterized as a safe and effective vaccine platform that eliminates pathogenicity and replication ability within the human body, designed to enhance antigen delivery efficiency and minimize vector-based side effects such as thrombosis. In addition to protective efficacy, GM-ChimAd-CV induced uniformly strong neutralizing antibodies against the Wuhan strain, Beta variant, and Delta variant, and physiological indicators such as body weight were also proven to correlate with the protective effect.

This content was produced with the assistance of AI translation services.